Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?
Guggenheim lowered Amgen's price target to $340, reflecting cautious sentiment amid biosimilar competition and a modest model update after Q1 2026 earnings.
Shoptalk: New Guggenheim Director Melissa Chiu on How She Got the Job | Artnet News
"We are uniquely global and local, historic and contemporary, collection driven and exhibition driven," Westermann said. "I really needed someone who understands that complexity."